This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: YM Bio, Exact, Peregrine

Having just 86 patients enrolled makes the bavi study more difficult to interpret. A smaller study is also more susceptible to differences in baseline characteristics of patients, so it will be important to see whether there are any significant differences in the patients enrolled in each arm of the study.

The bavi study is open label, meaning doctors and patients know if they're receiving bavi plus chemo or chemo alone. Open-label studies are more prone to biased results unless data is independently verified.

Peregrine's phase II study is enrolling lung cancer patients at 17 hospitals in the U.S., nine sites in India and 14 sites in Eastern Europe and Russia, according to a description of the study on Avastin plus chemo is the standard-of-care treatment for front-line lung cancer in the U.S., so how is Peregrine managing to enroll U.S. patients in a study that excludes Avastin?

Says Peregrine: "Avastin is not indicated for all front-line NSCLC [non-small cell lung cancer] patients, per independent research a minority of patients are treated with Avastin."

Genentech tells me that 40% of eligible lung cancer patients are treated with Avastin. Technically, that's a minority of patients, but certainly a large minority. Perhaps Peregrine is seeking "Avastin intolerant" patients for its bavi study. The company wouldn't tell me, specifically.

Peregrine did say that patients enrolled in the bavi study are "well-represented from the U.S., Europe and Asia." Peregrine wouldn't provide me a geographic breakdown of enrolled patients. I'd certainly be interested in seeing the data from the study parsed by geography. For instance, higher response rates among Indian patients have been documented in previously published studies.

Peregrine will be reporting additional data from this phase II study of bavi in 2012, including progression-free survival and overall survival. That's good because response rate is not a meaningful endpoint in lung cancer studies from a regulatory standpoint. A search through previous published lung cancer studies finds that improvements in tumor response rate don't always correlate to a survival benefit. Ultimately, Peregrine needs to demonstrate a survival benefit with bavi if it wants to see the drug approved.
5 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
EXAS $5.92 0.68%
INCY $70.69 0.40%
PPHM $0.33 -0.09%
SPPI $7.15 11.72%
AAPL $92.72 -0.56%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs